Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.34 |
| ▸ | PDE4A | P27815 | 9/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20939390 | 0.94 | MPO (0.38) | MPONLRP3PDE4BPDE4APDE4C | |
| SCHEMBL19431919 | 0.77 | MPO (0.42) | MPONLRP3PDE4BPDE4APDE4C | |
| SCHEMBL20939452 | 0.77 | MPO (0.42) | MPONLRP3PDE4BPDE4APDE4C | |
| SCHEMBL18338520 | 0.77 | MPO (0.42) | MPONLRP3PDE4BPDE4APDE4C | |
| SCHEMBL21863537 | 0.77 | HDAC1 (0.39) | MPONLRP3PDE4BPDE4APDE4C | |
| SCHEMBL21672110 | 0.77 | MPO (0.39) | MPONLRP3PDE4BPDE4APDE4C | |
| SCHEMBL18418855 | 0.77 | MPO (0.39) | MPONLRP3PDE4BPDE4APDE4C | |
| SCHEMBL29325037 | 0.77 | MPO (0.39) | MPONLRP3PDE4BPDE4APDE4C | |
| Hydrochloric Acid SCHEMBL26120934 | 0.76 | MPO (0.41) | MPONLRP3PDE4BPDE4APDE4C | |
| SCHEMBL1208389 | 0.74 | LMNA (0.45) | PDE4BIRAK4LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| WO-2024059249-A1 | M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3571187-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| WO-2023217851-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023159307-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | REPARE THERAPEUTICS INC. (CA) | 2023-08-31 | — | — | WO | disclosed |
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2023101981-A1 | SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102022-A1 | 4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-25 | — | — | US | disclosed |
| EP-3313838-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | disclosed |
| US-20170029413-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-02-02 | — | — | US | disclosed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | disclosed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | disclosed |
| US-8163901-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-8163901-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2011-02-03 | — | — | US | disclosed |
| WO-2009089057-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INS. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | MPO 2021/4885NLRP3 514/4885PDE4B 1320/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | MPO 556/4885NLRP3 3702/4885PDE4B 1120/4885 |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | MPO 2021/4885NLRP3 514/4885PDE4B 1320/4885 |
| US-20170029413-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, PRKAR2B, MAP3K13 | MPO 4789/4885NLRP3 4569/4885PDE4B 689/4885 |
| US-20190119299-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | MPO 1935/4885NLRP3 255/4885PDE4B 3165/4885 |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | MPO 556/4885NLRP3 8/4885PDE4B 2796/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MPO 538/4885NLRP3 2592/4885PDE4B 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.